Sirtex Medical Limited
ASX:SRX ISIN:AU000000SRX1
Sirtex Medical aims to become the world leader in liver cancer treatment products. The company believes the unmet demand for effective treatment of liver cancer provides an opportunity for the application of its products. Futhermore, Sirtex Medical aims to apply its micro-sphere technology to other diseases where the company's intellectual property can provide market opportunities.
News
Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.
Sirtex Medical (ASX:SRX)(PINK:SXMDF) has delivered record revenues and profit. Highlights include; total product revenue for the year ended 30 June 2009 was A$65.6 million, up 72 per cent on the previous year. Net profit after tax of A$18.2 million was up 1,406 per cent on the last year. SIR-Spheres microspheres dose sales were up 42 per cent to 3,658 doses.
Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) announced today the appointment of Mr Richard Hill as a non executive Director.
Sirtex Medical Limited (ASX: SRX) - Sirtex Medical to Sponsor FAST Clinical Trial - Dr Gilman Wong, CEO; Boardroomradio is pleased to announce that Sirtex Medical Limited (ASX: SRX) has published an audio file.
###
5,808 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 11) (Last 30 Days: 44) (Since Published: 5808)
